about
Adult primary paratesticular mesenchymal tumors with emphasis on a case presentation and discussion of spermatic cord leiomyosarcoma.Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification.An interobserver reproducibility study on invasiveness of bladder cancer using virtual microscopy and heatmaps.Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity.Morphologic and molecular backgrounds for personalized management of genito-urinary cancers: an overview.Pathological issues in biopsy specimens of men with prostate cancer eligible for active surveillance.BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients.Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy.Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets.Metabolic phenotype of bladder cancer.Mirna Expression in Bladder Cancer and Their Potential Role in Clinical Practice.Current Histopathologic and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies.A low grade PIN-like neoplasm of the transition zone immunohistochemically negative for basal cell markers: a possible example of low grade adenocarcinoma with stratified epithelium.Long Non-coding RNAs in Prostate Cancer with Emphasis on Second Chromosome Locus Associated with Prostate-1 Expression.Solitary fibrous tumour of the genitourinary tract: a clinicopathological study of 11 cases and their association with the NAB2-STAT6 fusion gene.Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 1 - kidney cancer.Intratumoural heterogeneity may hinder precision medicine strategies in patients with clear cell renal cell carcinoma.Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma.Loss of expression of the SWI/SNF complex is a frequent event in undifferentiated/dedifferentiated urothelial carcinoma of the urinary tract.Pathology of upper tract urothelial carcinoma with emphasis on staging.Prostate cancer grading in 2016.Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancerEmerging immunotherapeutic strategies targeting telomerases in genitourinary tumorsDataset for the reporting of carcinoma of renal tubular origin: recommendations from the International Collaboration on Cancer Reporting (ICCR)Histopathologic challenges: The second OPINION issueThe Identification of Immunological Biomarkers in Kidney CancersContemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureterNew Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane AntigenCirculating Tumor Cells in Renal Cell Carcinoma: Recent Findings and Future ChallengesMicrobiome and Cancers, With Focus on Genitourinary TumorsEmerging Molecular Technologies in Renal Cell Carcinoma: Liquid BiopsyVariants and new entities of bladder cancerStaging of bladder cancerLiquid biopsy in the clinical management of bladder cancer: current status and future developmentsUpdate of the International Consultation on Urological Diseases on bladder cancer 2018: non-urothelial cancers of the urinary bladderProstate Cancer Grading: Are We Heading Towards Grade Grouping Version 2?Re: Isabel Rauscher, Charlotte Düwel, Bernhard Haller, et al. Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical RecAn evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancerImmunotherapy in renal cell carcinoma from poverty to the spoiled of choice
P50
Q33688175-5EA51380-3F1C-4A2F-9619-752347D88A9BQ35925835-49459249-1035-451D-BE97-B3DCF79298DCQ38150460-C72570E6-13E9-43FB-8DD9-A36FD6FA59C1Q38214357-5C8AF5B3-0239-45F9-B4F8-0C2604C7640BQ38282194-C8819D55-D584-4AC1-8336-2C98ED43C9CDQ38340210-C5FBAAAA-E307-4A9D-A41B-E2CB890F046DQ38545726-27508F67-1723-4CA3-B07D-474F74BBB89CQ38676256-57DD9CB3-98D5-4491-95E4-6E0C7013FC25Q38759490-ED83E2E1-5631-4C98-885D-73B2DA8AF93DQ38763251-72FB7B3B-775B-4C75-B433-44B7C8F8DF10Q38774046-37AAD83F-D32B-4A69-A73A-005D2FD14E8FQ39317629-3861AAB3-9071-431D-9340-4A83FB599378Q40839914-0612105F-1F27-474B-A18B-D003357AAC34Q42450404-0B2D29E9-F573-4110-9AB5-36F9A80BD1EEQ47193237-1945D49A-FD0C-4F80-8783-879B3C5AC8A3Q47960083-E8305E7F-F12A-41DC-9FDA-7473E2A0BE55Q48085625-8B995A70-8C85-41F5-8F9E-8DCBC57E7E5AQ48277072-A6FED8D7-1FD6-4960-998E-FE3028D47DCCQ50912525-A9B6DEE8-04C1-43B4-8D65-8A477CBF458DQ51684531-823F1C65-8056-49C5-BFAA-69DFACDA0B3EQ53649386-38517852-CC5B-48BE-BAA9-3FA939D94BD7Q53741110-18F676DA-B129-4833-8F8E-6A5F8AC7C780Q56340896-3DEC169F-140F-4481-98CE-7BA9AFB9DA3DQ57181177-7110AB99-03BB-43E8-80D2-40C4CDF0D846Q57457513-2461F28E-9737-4051-A215-8655ACFA2BB2Q58552983-D3F7870B-FA41-42D7-A29F-13FAC147E3DDQ59132089-B66111C4-E3E0-445F-B252-99BC6800B1D6Q60918065-F780C4BB-0C19-41D0-B28D-BDFDEBE7C395Q60938851-0091E2BA-7C51-4B2A-9AFC-03363F90CAB8Q64071976-4269CF17-28A3-4611-B3F7-80247D542FB4Q64118740-B027BB71-4F91-4E1F-8637-A6145543CA94Q64246248-D0F35C71-C722-4326-A0C3-429DAE8289FBQ90628339-731A83A3-5821-48B1-842E-5552F32E6BCCQ90628342-DA05DCC2-85C8-4A62-815B-F198BF9C8E51Q90685077-3EA9E2AB-9E06-4F23-B85F-C9AB665F638BQ90703106-C6CD572F-C637-4510-AA45-3854F3FB6984Q90857793-01D45883-7B30-483D-B15E-C1397059DAF9Q90857797-E08BB9DF-9C58-4A40-A132-C6B0B587B897Q90879022-48DF0E0C-E44E-403B-85CA-2F0EE300310AQ90995926-A50B19DC-C7B0-492C-A0A0-E534437FC51A
P50
description
researcher (ORCID 0000-0002-0724-1267)
@en
name
Antonio Lopez-Beltran
@en
type
label
Antonio Lopez-Beltran
@en
prefLabel
Antonio Lopez-Beltran
@en
P31
P496
0000-0002-0724-1267